UBS Group AG (10% owner) bought 3,715 shares of NDRA at $0.55 on 2024-08-27; stock down -99.7% from 52-week high to $14.70.
UBS Group AG, a major 10% shareholder in ENDRA Life Sciences, purchased 3,715 shares at $0.55 on 2024-08-27, adding modestly to its 146,012-share position (+2.6% vs pre-transaction holdings). The stock has since cratered -99.7% from its 52-week high and is down -90.2% over the past 30 days and -96.9% over 90 days. ENDRA posted $0.00 revenue in its latest quarter and $-2,229,153.00 net income for the period, reflecting a deeply unprofitable operating profile with a $1.1B market cap. While UBS's cross-ticker track record shows strong historical returns on prior buys (avg 30d return +2593.6%), this purchase occurred at a price that has proven to be the start of a severe drawdown, not an opportune accumulation point.